Abstract
Purpose
To compare transarterial chemoembolization (TACE), transarterial radioembolization using Yttrium-90 (TARE), and transarterial ethanol ablation (TEA) for huge hepatocellular carcinoma (HCC) in treatment responses and long-term survival outcomes.
Materials and Methods
In this retrospective study approved by institutional committee, inclusion criteria were tumour ≥ 10 cm, newly diagnosed, treatment naïve, Child A, Performance Score 0 or 1, no venous invasion or extrahepatic disease on contrast-enhanced CT or MRI. There were 107 patients (Supportive Care [SC] 17, TACE 54, TARE 17, TEA 19). Survival outcomes of SC and TACE were compared (TACE selected as benchmark for transarterial treatments). Tumour response and overall survival (OS) of the three groups were compared.
Results
OS of TACE (vs. SC) was significantly longer (9.9 [5.9, 24.1] months versus 2.8 [1.5, 10.2], p = 0.001). Complete response of TEA was significantly better (TEA 10/19 [52.6%] versus TARE 2/17 [12.5%], p = 0.013, versus TACE 9/54 [16.7%], p = 0.002). OS of TEA (vs. TACE) was significantly longer (21.6 [12, 41] months versus 9.9 [5.9, 24.1], p = 0.014, hazard ratio 0.6 (0.3, 1). OS of TEA (vs. TARE) was longer (21.6 [12, 41] months versus 11.9 [7, 28.7], p = 0.082, hazard ratio 0.6 (0.3, 1.3) in favour of TEA).
Conclusion
In patients with huge HCC, transarterial treatment as represented by TACE had a survival benefit over supportive care. In this retrospective analysis, TEA was associated with better tumour response and survival outcome as compared to TACE or TARE; therefore, transarterial treatment could be useful for prolonging patient survival, and TEA could be a preferred option.
Similar content being viewed by others
References
Raoul JL, Sangro B, Forner A, et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev. 2011;37:212–20. https://doi.org/10.1016/j.ctrv.2010.07.006.
Peng ZW, Chen SL, Wei MC, et al. Advanced recurrent hepatocellular carcinoma: treatment with sorafenib alone or in combination with transarterial chemoembolization and radiofrequency ablation. Radiology. 2018;287:705–14. https://doi.org/10.1148/radiol.2018171541.
Kok VC, Chen YC, Chen YY, et al. Sorafenib with transarterial chemoembolization achieves improved survival vs. sorafenib alone in advanced hepatocellular carcinoma: a nationwide population-based cohort study. Cancers. 2019;11:985–8. https://doi.org/10.3390/cancers11070985.
Salem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011;140(497–507):e2. https://doi.org/10.1053/j.gastro.2010.10.049.
Salem R, Gordon AC, Mouli S, et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2016;151:1155–63. https://doi.org/10.1053/j.gastro.2016.08.029.
Yu SCH, Hui JW, Hui EP, et al. Embolization efficacy and treatment effectiveness of transarterial therapy for unresectable hepatocellular carcinoma: a case-controlled comparison of transarterial ethanol ablation with lipiodol-ethanol mixture versus transcatheter arterial chemoembolization. J Vasc Interv Radiol. 2009;20:352–9. https://doi.org/10.1016/j.jvir.2008.12.407.
Yu SC, Hui JW, Hui EP, et al. Unresectable hepatocellular carcinoma: randomized controlled trial of transarterial ethanol ablation versus transcatheter arterial chemoembolization. Radiology. 2014;270:607–20. https://doi.org/10.1148/radiol.13130498.
Yu SC, Hui EP, Tang P, et al. Transarterial ethanol ablation for unresectable hepatocellular carcinoma: analysis of clinical and tumor outcomes. J Vasc Interv Radiol. 2016;27:639–49. https://doi.org/10.1016/j.jvir.2015.11.032.
Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33:550–8. https://doi.org/10.1200/JCO.2014.57.9151.
Forner A, Ayuso C, Varela M, et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer. 2009;115:616–23. https://doi.org/10.1002/cncr.24050.
Riaz A, Memon K, Miller FH, et al. Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. J Hepatol. 2011;54:695–704. https://doi.org/10.1016/j.jhep.2010.10.004.
Salem R, Lewandowski RJ, Gates VL, et al. Research reporting standards for radioembolization of hepatic malignancies. J Vasc Interv Radiol. 2011;22:265–78. https://doi.org/10.1016/j.jvir.2010.10.029.
Filippiadis DK, Binkert C, Pellerin O, Hoffmann RT, Krajina A, Pereira PL. Cirse quality assurance document and standards for classification of complications: the cirse classification system. Cardiovasc Intervent Radiol. 2017;40:1141–6. https://doi.org/10.1007/s00270-017-1703-4.
Robert J, Lewandowski RJ, Sato KT, et al. Radioembolization with 90Y microspheres: angiographic and technical considerations. Cardiovasc Intervent Radiol. 2007;30:571–92. https://doi.org/10.1007/s00270-007-9064-z.
Bilbao JI, Garrastachu P, Herraiz MJ, et al. Safety and efficacy assessment of flow redistribution by occlusion of intrahepatic vessels prior to radioembolization in the treatment of liver tumors. Cardiovasc Intervent Radiol. 2009;33:523–31. https://doi.org/10.1007/s00270-009-9717-1.
Leung TW, Lau WY, Ho SK, et al. Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttriummicrospheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys. 1995;33:919–24. https://doi.org/10.1016/0360-3016(95)00039-3.
Ho S, Lau WY, Leung TW, et al. Tumour-to-normal uptake ratio of 90Y microspheres in hepatic cancer assessed with 99Tcm macroaggregated albumin. Br J Radiol. 1997;70:823–8. https://doi.org/10.1259/bjr.70.836.9486047.
Ho S, Lau WY, Leung TW, et al. Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours. Eur J Nucl Med. 1996;23:947–52. https://doi.org/10.1007/BF01084369.
Huang YH, Wu JC, Chen SC, et al. Survival benefit of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma larger than 10 cm in diameter. Aliment Pharmacol Ther. 2005;23:129–35. https://doi.org/10.1111/j.1365-2036.2006.02704.x.
Xue T, Le F, Chen R, et al. Transarterial chemoembolization for huge hepatocellular carcinoma with diameter over ten centimeters: a large cohort study. Med Oncol. 2015;32:64. https://doi.org/10.1007/s12032-015-0504-3.
Chen JH, Wei CK, Lee CH, Chang CM, Yin WY. Better long-term prognosis: comparison between surgery and TACE as initial treatment for operable huge HCCs (≥10 cm) after more than 5 years of follow up. Int Surg. 2017;102:244–9. https://doi.org/10.9738/INTSURG-D-14-00316.1.
Miyayama S, Kikuchi Y, Yoshida M, et al. Outcomes of conventional transarterial chemoembolization for hepatocellular carcinoma ≥ 10 cm. Hepatol Res. 2019;49:787–98. https://doi.org/10.1111/hepr.13335.
Basile A, Carrafiello G, Ierardi AM, Tsetis D, Brountzos E. Quality-improvement guidelines for hepatic transarterial chemoembolization. Cardiovasc Intervent Radiol. 2012;35:765–74. https://doi.org/10.1007/s00270-012-0423-z.
Chung JW, Park JH, Im JG, Han JK, Han MC. Pulmonary oil embolism after transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology. 1993;187:689–93. https://doi.org/10.1148/radiology.187.3.8388567.
Acknowledgements
The authors would like to thank Miss Tiffany Lau and Mr. Kwok-Tung Lee for their help in this study.
Funding
This study was funded by Vascular and Interventional Radiology Foundation. The funding body had not involved in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical Approval
For this type of study formal consent is not required. This study was approved by Institutional Review Board.
Informed Consent
This study has obtained IRB approval from (indicate the relevant board) and the need for informed consent was waived.
Consent for Publication
For this type of study consent for publication is not required.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Yu, S.C.H., Hui, J.WY., Li, L. et al. Comparison of Chemoembolization, Radioembolization, and Transarterial Ethanol Ablation for Huge Hepatocellular Carcinoma (≥ 10 cm) in Tumour Response and Long-Term Survival Outcome. Cardiovasc Intervent Radiol 45, 172–181 (2022). https://doi.org/10.1007/s00270-021-02777-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00270-021-02777-6